MIRA Pharmaceuticals Enhances Ketamir-2 with Topical Pain Treatment

MIRA Pharmaceuticals has formulated Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain, broadening its pain management portfolio. This new approach complements their existing oral treatment, allowing targeted pain relief directly at the application site with minimal side effects. The topical treatment aims to address conditions like diabetic neuropathy, rheumatoid arthritis, and carpal tunnel syndrome.

Current pain treatments such as NSAIDs, lidocaine patches, and opioids often provide limited relief and have significant side effects. MIRA's topical Ketamir-2 intends to overcome these issues, offering effective and lasting pain relief without systemic risks. The company continues to advance clinical and preclinical programs, including studies investigating Ketamir-2's potential for treating PTSD and diabetic neuropathy, promising expansion into neuropsychiatric applications.